帕瑞肽在胰十二指肠切除术中的前瞻性评估:华盛顿大学经验
该前瞻性研究纳入459例胰十二指肠切除术患者,其中127例(28%)接受帕瑞肽。倾向性评分匹配后,帕瑞肽未显著减少胰瘘发生率或严重程度,但术后出血/贫血发生率显著降低(9.8% vs 19.6%,p=0.04)。
要点
- 帕瑞肽未降低胰十二指肠切除术后胰瘘发生率或严重程度。
- 帕瑞肽与术后出血/贫血发生率显著降低相关。
- 需要多中心随机试验明确帕瑞肽在该人群中的作用。
核心结论
- 帕瑞肽未减少胰十二指肠切除术后胰瘘的发生率或严重程度,但与术后出血/贫血减少相关。
研究设计与样本
- 前瞻性队列研究,纳入2011年4月至2017年1月共459例胰十二指肠切除术患者,其中127例(28%)接受帕瑞肽,并进行倾向性评分匹配比较结局。
主要发现
- 帕瑞肽组与未用药组在胰瘘、总体并发症、90天再入院或90天死亡率方面无差异。
- 帕瑞肽组术后出血/贫血发生率显著降低(8.7% vs 16.9%,p=0.03)。
- 112对倾向性评分匹配后,严重胰瘘(MAGS 3-6级)发生率两组均为7.1%(p=1.00)。
- 匹配患者中帕瑞肽组术后出血/贫血显著减少(9.8% vs 19.6%,p=0.04)。
临床怎么用
- 对于胰十二指肠切除术患者,帕瑞肽虽不能降低胰瘘风险,但可能有助于减少术后出血/贫血。
局限性
- 单中心研究,帕瑞肽使用非随机,需多中心随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pasireotide is a newer generation somatostatin analogue that led to a significant reduction in pancreatic fistula after pancreatectomy in a single-center randomized controlled trial. We sought to determine if pasireotide reduces the incidence of pancreatic fistula and other complications after pancreaticoduodenectomy at our high volume center. STUDY DESIGN: All patients undergoing pancreaticoduodenectomy between April 2011 and January 2017 were prospectively followed, and their complications were graded using the Modified Accordion Grading System (MAGS) in our institutional complications database. For 18 months, 5 pancreatic surgeons used pasireotide routinely in patients undergoing pancreaticoduodenectomy. Patients receiving pasireotide were then propensity score-matched to patients who did not receive pasireotide, and their outcomes were compared. RESULTS: There were 459 patients who underwent pancreaticoduodenectomy, and 127 patients (28%) received pasireotide. Patients who received pasireotide were significantly more likely to have dilated pancreatic ducts and have a drain left at the time of surgery. Patients who received pasireotide had no difference in pancreatic fistula, overall complications, 90-day readmission, or 90-day mortality. However, patients who received pasireotide had a significantly reduced rate of postoperative bleeding/anemia (8.7% vs 16.9%, p = 0.03). Among 112 propensity score-matched pairs, patients who received pasireotide did not have significantly different rates of pancreatic fistula, and the rates of severe (MAGS grades 3 to 6) pancreatic fistula were identical between the 2 groups (7.1% vs 7.1%, p = 1.00). Matched patients who received pasireotide had significantly decreased postoperative bleeding/anemia (9.8% vs 19.6%, p = 0.04). CONCLUSIONS: Pasireotide did not reduce the incidence or severity of pancreatic fistulas after pancreaticoduodenectomy, but was associated with a decrease in postoperative bleeding/anemia. A multicenter randomized trial is needed to accurately define the role of pasireotide in the postoperative management of pancreaticoduodenectomy patients.
引用
- Dominguez-Rosado I, Fields RC, Woolsey CA, et al. Prospective Evaluation of Pasireotide in Patients Undergoing Pancreaticoduodenectomy: The Washington University Experience. J Am Coll Surg. 2017. PMID: 29133263. doi:10.1016/j.jamcollsurg.2017.10.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。